Toronto, Ontario--(Newsfile Corp. - February 25, 2020) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company") , a developer of MedTech innovation, is pleased to announce the completion of the HemoPalm-CX™, a proof-of-principle prototype compact POCT instrument that directly measures five CO-oximetry components from human whole blood. The system uses proprietary optics and data analysis technology developed by the Company's HemoPalm diagnostics division.
Relay's HemoPalm-CX technology enables the direct measurement of unprocessed whole blood, without the need for red blood cell hemolysis as found in some larger benchtop systems (and not available in current handheld devices). The technology features a compact optical system, single-use sample cartridges, and cloud connectivity. The cartridges are designed for cost-effective high-volume manufacturing, have a long shelf-life, and can be stored at room temperature. Operation is quick and simple, conducting a full CO-oximetry panel of tests on whole human blood in seconds, as demonstrated in the video below.
VIDEO: HemoPalm Proof of Principle Prototype Demonstration
https://youtu.be/TFxwuP8NkLA
The HemoPalm-CX incorporates the following features:
- Compact portable device
- Rapid time to results
- Battery operated
- No maintenance
- No on-board fluids or wastes
- Bi-directional cloud connectivity with remotely accessible results
- Small sample volume (40 μL)
- No sample preparation
- Easy sample delivery from syringe
- Long cartridge shelf-life with room temperature storage
The HemoPalm-CX has been designed as a small-footprint, portable, near-patient device to compliment existing workflow in critical care settings. Due to the small size, robustness, and flexibility of the core measurement technology, Relay has also developed concepts for additional instrument formats, including handheld form factors and a cloud-based mini version for use with a smartphone or tablet. The current prototype device also connects to a portable printer using wireless connectivity.
Figure 1: HemoPalm-CX Proof-of-principle prototype (left) with cartridge and portable printer (center) and mock-up of handheld instrument concept (right)
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/952/52788_2780b899a43e8a7f_001full.jpg
Figure 2: HemoPalm-CX Optical Module
To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/952/52788_2780b899a43e8a7f_002full.jpg
Figure 3: Concept for mini HemoPalm-CX for use with smartphone/tablet
To view an enhanced version of Figure 3, please visit:
https://orders.newsfilecorp.com/files/952/52788_2780b899a43e8a7f_003full.jpg
CO-oximetry measurements are crucial in critical care settings such as the Intensive Care Unit, Cardiac Care Unit, Neonatal Intensive Care Unit, Emergency Department and Emergency Medical Services. In addition to providing hemoglobin fractions that are critical to a full understanding of a patient's oxygenation status, the accurate total hemoglobin (and calculated hematocrit) can facilitate blood transfusion decisions, particularly where POCT blood gas instruments only provide unreliable conductimetric hematocrit measurements. The HemoPalm-CX complements many bedside and near-patient blood gas analyzers that do not have CO-oximetry capabilities.
The completion of the HemoPalm-CX proof-of-principle prototype advances Relay Medical's goal of developing an industry-leading stand-alone POCT technology that can be either sold directly by Relay or co-marketed/co-branded with other established manufacturers. The small size of the device highlights the ability to offer Relay's proprietary technology for field use outside of hospitals, alone at the hospital point-of-care, or combined with existing POCT instruments for improved critical care testing. The latter supports a commercial path of licensing the HemoPalm-CX technology for incorporation into one or more commercial platforms lacking reliable whole blood CO-oximetry.
Relay Medical intends to continue discussions with potential development and licencing partners and is targeting large established medical device companies as well as emerging blood gas and POCT companies in developing markets.
About Relay Medical Corp.
Relay Medical is a MedTech innovation Company headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and data science sectors.
Website: www.relaymedical.com
Contact:
W. Clark Kent
President
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@relaymedical.com
Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for HemoPalm Corp. described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52788
